Literature DB >> 23716709

Peripheral muscle microcirculatory alterations in patients with pulmonary arterial hypertension: a pilot study.

Stavros Dimopoulos1, Georgios Tzanis, Christos Manetos, Athanasios Tasoulis, Anthi Mpouchla, Eleni Tseliou, Ioannis Vasileiadis, Nikos Diakos, John Terrovitis, Serafim Nanas.   

Abstract

BACKGROUND: Pulmonary microcirculation abnormalities are the main determinants of pulmonary arterial hypertension (PAH) pathophysiology. We hypothesized that PAH patients have peripheral tissue microcirculation alterations that might benefit from hyperoxic breathing. We evaluated peripheral muscle microcirculation with near-infrared spectroscopy, before and after hyperoxic breathing.
METHODS: Eight PAH subjects, 8 healthy subjects (controls) matched for age, sex, and body mass index, and 16 subjects with chronic heart failure and matched for functional capacity with the PAH subjects underwent near-infrared spectroscopy. Tissue O(2) saturation, defined as the hemoglobin saturation (%) in the microvasculature compartments, was measured on the thenar muscle. Then the 3-min brachial artery occlusion technique was applied before, during, and after 15 min of breathing 100% O(2). We calculated the oxygen consumption rate (%/min), the reactive hyperemia time, and the time needed for tissue O(2) saturation to reach its baseline value after the release of the occlusion.
RESULTS: Compared to the controls, the PAH subjects had a significantly lower resting tissue O(2) saturation (65.8 ± 14.9% vs 82.1 ± 4.0%, P = .005), a trend toward a lower oxygen consumption rate (35.3 ± 9.1%/min vs 43.4 ± 19.7%/min, P = .60), and a significantly higher reactive hyperemia time (3.0 ± 0.6 min vs 2.0 ± 0.3 min, P < .001). The PAH subjects also had lower tissue O(2) saturation (P = .08), lower peripheral arterial oxygen saturation (P = .01), and higher reactive hyperemia time (P = .02) than the chronic heart failure subjects. After hyperoxic breathing, the PAH subjects had increased tissue O(2) saturation (65.8 ± 14.9% to 71.4 ± 14.5%, P = .01), decreased oxygen consumption rate (35.3 ± 9.1%/min to 25.1 ± 6.6%/min, P = .01), and further increased reactive hyperemia time (3.0 ± 0.6 min to 4.2 ± 0.7 min, P = .007).
CONCLUSIONS: The PAH subjects had substantial impairments of peripheral muscle microcirculation, decreased tissue O(2) saturation (possibly due to hypoxemia), slower reactive hyperemia time, (possibly due to endothelium dysfunction), and peripheral systemic vasoconstriction. Acute hyperoxic breathing improved resting tissue O(2) saturation (an expression of higher oxygen delivery) and decreased the oxygen consumption rate and reactive hyperemia time during reperfusion, possibly due to increased oxidative stress and evoked vasoconstriction.

Entities:  

Keywords:  endothelium; hyperoxia; microcirculation; near-infrared spectroscopy; oxygen breathing; pulmonary arterial hypertension

Mesh:

Substances:

Year:  2013        PMID: 23716709     DOI: 10.4187/respcare.02113

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  12 in total

Review 1.  Respiratory and limb muscle dysfunction in pulmonary arterial hypertension: a role for exercise training?

Authors:  Marios Panagiotou; Andrew J Peacock; Martin K Johnson
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

2.  Sublingual microcirculation in pulmonary arterial hypertension.

Authors:  Luma Dababneh; Frank Cikach; Laith Alkukhun; Raed A Dweik; Adriano R Tonelli
Journal:  Ann Am Thorac Soc       Date:  2014-05

Review 3.  Clinical value of non-coding RNAs in cardiovascular, pulmonary, and muscle diseases.

Authors:  Sébastien Bonnet; Olivier Boucherat; Roxane Paulin; Danchen Wu; Charles C T Hindmarch; Stephen L Archer; Rui Song; Joseph B Moore; Steeve Provencher; Lubo Zhang; Shizuka Uchida
Journal:  Am J Physiol Cell Physiol       Date:  2019-09-04       Impact factor: 4.249

Review 4.  Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension.

Authors:  Nils P Nickel; Ke Yuan; Peter Dorfmuller; Steeve Provencher; Yen-Chun Lai; Sebastien Bonnet; Eric D Austin; Carl D Koch; Alison Morris; Frédéric Perros; David Montani; Roham T Zamanian; Vinicio A de Jesus Perez
Journal:  Am J Respir Crit Care Med       Date:  2020-01-15       Impact factor: 21.405

5.  The effects of pulmonary hypertension on skeletal muscle oxygen pressures in contracting rat spinotrapezius muscle.

Authors:  Kiana M Schulze; Ramona E Weber; Trenton D Colburn; Andrew G Horn; Carl J Ade; Wei-Wen Hsu; David C Poole; Timothy I Musch
Journal:  Exp Physiol       Date:  2021-09-17       Impact factor: 2.858

Review 6.  Exercise training in pulmonary arterial hypertension.

Authors:  Laura Adelaide Dalla Vecchia; Maurizio Bussotti
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

7.  Effects of pulmonary hypertension on microcirculatory hemodynamics in rat skeletal muscle.

Authors:  Kiana M Schulze; Ramona E Weber; Andrew G Horn; Trenton D Colburn; Carl J Ade; David C Poole; Timothy I Musch
Journal:  Microvasc Res       Date:  2022-01-30       Impact factor: 3.514

8.  Epigenetics of Notch1 regulation in pulmonary microvascular rarefaction following extrauterine growth restriction.

Authors:  Li-Li Tang; Li-Yan Zhang; Lin-Jiang Lao; Qiong-Yao Hu; Wei-Zhong Gu; Lin-Chen Fu; Li-Zhong Du
Journal:  Respir Res       Date:  2015-06-04

9.  Randomised controlled trial examining the effect of an outpatient exercise training programme on haemodynamics and cardiac MR parameters of right ventricular function in patients with pulmonary arterial hypertension: the ExPAH study protocol.

Authors:  Karen S W Chia; Steven G Faux; Peter K K Wong; Cameron Holloway; Hassan Assareh; Craig S McLachlan; Eugene Kotlyar
Journal:  BMJ Open       Date:  2017-02-06       Impact factor: 2.692

10.  Involvement of Ca2+-activated K+ channel 3.1 in hypoxia-induced pulmonary arterial hypertension and therapeutic effects of TRAM-34 in rats.

Authors:  Shujin Guo; Yongchun Shen; Guangming He; Tao Wang; Dan Xu; Fuqiang Wen
Journal:  Biosci Rep       Date:  2017-07-27       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.